JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB7152

Goat Anti-Human IgG H&L (Biotin) preadsorbed

Be the first to review this product! Submit a review

|

(6 Publications)

Suitable for WB, Dot, IHC-P, IM, ICC/IF, ELISA. Preadsorbed to minimise non-specific binding and high background staining. Cited in 6 publications.

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1, Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4, Immunoglobulin heavy constant gamma 3, HDC, Heavy chain disease protein, Ig gamma-3 chain C region, IGHG3, Immunoglobulin heavy constant gamma 2, Ig gamma-2 chain C region, Ig gamma-2 chain C region DOT, Ig gamma-2 chain C region TIL, Ig gamma-2 chain C region ZIE, IGHG2

1 Images
Western blot - Goat Anti-Human IgG H&L (Biotin) preadsorbed (AB7152)
  • WB

Supplier Data

Western blot - Goat Anti-Human IgG H&L (Biotin) preadsorbed (AB7152)

Western blot analysis of ab7152. Secondary antibody : Peroxidase Streptavidin secondary antibody at 1/40000 dilution for 30 min at RT.

All lanes:

Western blot - Goat Anti-Human IgG H&L (Biotin) preadsorbed (ab7152) at 1/1000 dilution

All lanes:

Human IgG at 50 ng

Secondary

All lanes:

Peroxidase Streptavidin secondary antibody at 1/40000 dilution

false

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

Heavy & Light chains

Minimal cross-reactivity

Mouse, Rat, Sheep, Rabbit, Goat, Horse, Chicken, Guinea pig, Hamster, Cow,

Pre-adsorbed

Yes

Conjugation

Biotin

Excitation/Emission
Applications

ELISA, WB, IM, ICC/IF, Dot, IHC-P

applications

Clonality

Polyclonal

Immunogen

Native Full Length Protein corresponding to Human IGHG1.

P01857

Specificity

No reaction was observed against Bovine, Chicken, Goat, Guinea Pig, Hamster, Horse, Mouse, Rabbit, Rat and Sheep Serum Proteins.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/2000 - 1/10000", "notes":"<p></p>" }, "Dot": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"", "notes":"<p></p>" }, "IHC-P": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/500 - 1/2500", "notes":"<p></p>" }, "IM": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"", "notes":"<p></p>" }, "ICC/IF": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/1000 - 1/5000", "notes":"<p></p>" }, "ELISA": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/200000", "notes":"<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Purification notes
Secondary antibody conjugate was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities.
Storage buffer
Preservative: 0.01% Sodium azide Constituents: 1% BSA, 0.88% Sodium chloride, 0.424% Potassium phosphate solution
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Product protocols

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region of Ig gamma-1 (IgG1) isotype interacts (via the fragment crystallizable, Fc) with receptors on innate immune cells and the complement system to mediate humoral effector functions, including antibody-dependent cellular cytotoxicity or phagocytosis, complement-dependent cytotoxicity and inflammatory responses.
See full target information IGHG1

Additional targets

IGHG3,IGHG2,IGHG4

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

ACS nano 17:23545-23567 PubMed37988765

2023

Single-Component Multilayered Self-Assembling Protein Nanoparticles Displaying Extracellular Domains of Matrix Protein 2 as a Pan-influenza A Vaccine.

Applications

Unspecified application

Species

Unspecified reactive species

Keegan Braz Gomes,Yi-Nan Zhang,Yi-Zong Lee,Mor Eldad,Alexander Lim,Garrett Ward,Sarah Auclair,Linling He,Jiang Zhu

Journal of pharmaceutical sciences 113:72-84 PubMed37844759

2023

Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models.

Applications

Unspecified application

Species

Unspecified reactive species

Jun Wang,Ting Chen,Donna M Ruszaj,Donald E Mager,Robert M Straubinger

Nature communications 14:1985 PubMed37031217

2023

Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates.

Applications

Unspecified application

Species

Unspecified reactive species

Yi-Nan Zhang,Jennifer Paynter,Aleksandar Antanasijevic,Joel D Allen,Mor Eldad,Yi-Zong Lee,Jeffrey Copps,Maddy L Newby,Linling He,Deborah Chavez,Pat Frost,Anna Goodroe,John Dutton,Robert Lanford,Christopher Chen,Ian A Wilson,Max Crispin,Andrew B Ward,Jiang Zhu

Science advances 7:eabj3107 PubMed34669468

2021

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.

Applications

Unspecified application

Species

Unspecified reactive species

Yi-Nan Zhang,Jennifer Paynter,Cindy Sou,Tatiana Fourfouris,Ying Wang,Ciril Abraham,Timothy Ngo,Yi Zhang,Linling He,Jiang Zhu

bioRxiv : the preprint server for biology : PubMed33791704

2021

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.

Applications

Unspecified application

Species

Unspecified reactive species

Yi-Nan Zhang,Jennifer Paynter,Cindy Sou,Tatiana Fourfouris,Ying Wang,Ciril Abraham,Timothy Ngo,Yi Zhang,Linling He,Jiang Zhu

Science translational medicine 5:187ra72 PubMed23720583

2013

Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza.

Applications

Unspecified application

Species

Human

Maria P Limberis,Virginie S Adam,Gary Wong,Jason Gren,Darwyn Kobasa,Ted M Ross,Gary P Kobinger,Anna Tretiakova,James M Wilson
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com